Here's something you don't see every day: a medical device that uses gentle electrical stimulation to change how the brain talks to itself, and in doing so, might help teenagers who hurt themselves stop doing it. That's the promise from a new study on Nexalin Technology, Inc. (NXL)'s Deep Intracranial Frequency Stimulation (DIFS) technology, published Thursday in the journal BMC Psychiatry.
The data is early—it's from just six patients—but the results are striking. In female adolescents struggling with non-suicidal self-injury (NSSI), using Nexalin's 77.5 Hz high-gamma approach was associated with "statistically significant reductions in self-injury behaviors and depressive symptoms." Think about that for a second. We're talking about a behavior that is incredibly difficult to treat, often resistant to therapy and medication, showing improvement after a non-invasive, drug-free intervention.
But here's the really interesting part: the study didn't just ask the patients how they felt. It looked inside their heads. The paper reports "measurable changes in brain-network activity and connectivity" across networks involved in emotional control, including the Default, Limbic, Salience/Ventral Attention, and Control networks. In plain English, the device seems to be helping different parts of the brain that handle emotion and impulse control communicate better. The findings also showed improvements in anxiety and sleep quality.
On the safety front, it was remarkably clean. The analysis of the six patients who received 21 days of stimulation reported "no significant adverse effects," with only one mild headache that resolved quickly. The authors are careful to note this is "preliminary evidence supporting further investigation in larger randomized controlled trials." Translation: this is a promising signpost, not the final destination.
For the company, this is about building a scientific case, brick by brick. "This publication is important because it extends the scientific case for Nexalin's high-gamma DIFS technology into one of the most urgent and difficult-to-treat populations in mental health," said David Owens, Chief Medical Officer of Nexalin. He added, "We believe these findings further support the underlying mechanism of our 77.5 Hz, 15 mA neurostimulation approach and add to the growing body of peer-reviewed evidence validating Nexalin's platform."
CEO Mark White framed it in terms of market need. "The Nexalin 15 mAmp DIFS technology allows for deeper penetration, which supports higher efficacy and enhanced treatment outcomes in a treatment-resistant population," he said. "In a market seeking safer, drug-free alternatives in mental health, each additional peer-reviewed publication helps further validate our technology and broaden its relevance across multiple indications."
It's part of a broader push by the company. Back in February, Nexalin launched a new AI-designed virtual clinic platform called NeuroCare in collaboration with the University of California, San Diego. That launch was pitched as the first step in a digital health ecosystem meant to increase patient access, reduce costs, and provide long-term care monitoring for various brain-health conditions.
As for the market's immediate reaction? Shares of Nexalin closed at $0.35 on Wednesday. The story for investors isn't just about one study; it's about whether this stream of peer-reviewed evidence can translate into a viable treatment for some of mental health's toughest challenges.
